GlassScriptPhysician profile
Matthew E Battaglia
NPI 1972818227
$4,800.21
in general payments reported to CMS, 2019-2025
19 companies · $3,357 in 2025
The $3,357 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $369 · 2023: $333 · 2024: $431 · 2025: $3,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,625 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,625.00 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,595.27 | 2022-2025 | |
| Alkermes, INC. | $548.01 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $377.27 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $302.14 | 2023-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $211.27 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $176.23 | 2025 | Qelbree |
| Corium, LLC | $160.66 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $82.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $68.64 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Tris Pharma INC | $53.00 | 2021 | |
| Orexo US, INC. | $45.76 | 2024-2025 | Zubsolv |
| Sunovion Pharmaceuticals INC. | $32.89 | 2021 | |
| Janssen Pharmaceuticals, INC | $32.47 | 2025 | Spravato |
| Vanda Pharmaceuticals INC. | $23.89 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $21.77 | 2024 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.21 | 2024 | 2nd Gen Centrimag Primary Console |
| Uswm, LLC | $19.08 | 2024 | Lucemyra |
| Indivior INC. | $16.54 | 2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Battaglia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.